Highest development stage: Approved for topical use by FDA in 1997

Development status: Approved

Gram-positive activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Active against Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes

Additional information: Natural product from Pseudomonas fluorescens; used topically but not systemically (compound is rapidly hydrolysed to inactive metabolites in the latter case)